Cytokine conjugates for the treatment of proliferative and infectious diseases
Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).
1. A modified interleukin-2 (IL-2) polypeptide comprising:
a. at least one unnatural amino acid; and
b. a conjugating moiety covalently attached via a linker to the at least one unnatural amino acid;
wherein the conjugating moiety is a water-soluble polymer, wherein the position of the at least one unnatural amino acid is selected from K35, T37, R38, T41, F42, K43, F44, Y45, E60, E61, E62, K64, P65, E68, V69, N71, L72, M104, C105, and Y107,
wherein the residue positions correspond to the positions 35, 37, 38, 41, 42, 43, 44, 45, 60, 61, 62, 64, 65, 68, 69, 71, 72, 104, 105, and 107 as set forth in SEQ ID NO: 1, and
wherein the modified interleukin-2 (IL-2) polypeptide comprises at least 80% sequence identity to SEQ ID NO: 1.
2. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein the modified interleukin-2 (IL-2) polypeptide comprises at least 90% sequence identity to SEQ ID NO: 1.
3. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein the position of the at least one unnatural amino acid is selected from T37, R38, T41, F42, K43, F44, Y45, E61, E62, P65, E68, and L72, wherein the residue positions correspond to the positions 37, 38, 41, 42, 43, 44, 45, 61, 62, 65, 68, and 72 as set forth in SEQ ID NO: 1.
4. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein the position of the at least one unnatural amino acid is selected from K35, K64, V69, N71, M104, C105, and Y107, wherein the residue positions correspond to the positions 35, 64, 69, 71, 104, 105, and 107 as set forth in SEQ ID NO: 1.
5. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein the position of the at least one unnatural amino acid is selected from T37, R38, T41, Y45, E61, E68, and L72, wherein the residue positions correspond to the positions 37, 38, 41, 45, 61, 68, and 72 as set forth in SEQ ID NO: 1.
6. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein the position of the at least one unnatural amino acid is selected from F42, K43, F44, E62, and P65, wherein the residue positions correspond to the positions 42, 43, 44, 62, and 65 as set forth in SEQ ID NO: 1.
7. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein the at least one unnatural amino acid is a lysine analogue or comprises an aromatic side chain.
8. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein (a) the conjugating moiety comprises polyethylene glycol (PEG), and (b) the at least one unnatural amino acid is selected from F42, K43, F44, Y45, E62, and P65, and wherein the residue positions correspond to the positions 42, 43, 44, 45, 62, and 65 as set forth in SEQ ID NO: 1.
9. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein the water-soluble polymer comprises polyethylene glycol (PEG), poly(propylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(α-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(N-acryloylmorpholine), poly[oligo(ethylene glycol)methyl methacrylate] (POEGMA), or a combination thereof.
10. The modified interleukin-2 (IL-2) polypeptide of claim 9 , wherein the water-soluble polymer comprises polyethylene glycol (PEG).
11. The modified interleukin-2 (IL-2) polypeptide of claim 10 , wherein the polyethylene glycol (PEG) has a weight-average molecular weight of from about 100 Daltons to about 150,000 Daltons.
12. The modified interleukin-2 (IL-2) polypeptide of claim 11 , wherein the polyethylene glycol (PEG) has a weight-average molecular weight of from about 10,000 Daltons to about 85,000 Daltons.
13. The modified interleukin-2 (IL-2) polypeptide of claim 12 , wherein the polyethylene glycol (PEG) has a weight-average molecular weight of from about 20,000 Daltons to about 85,000 Daltons.
14. The modified interleukin-2 (IL-2) polypeptide of claim 13 , wherein the polyethylene glycol (PEG) has a weight-average molecular weight selected from about 20,000 Daltons, about 25,000 Daltons, about 30,000 Daltons, about 35,000 Daltons, about 40,000 Daltons, about 45,000 Daltons, or about 50,000 Daltons.
15. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein:
a. the position of the at least one unnatural amino acid is selected from F42, K43, F44, E62, and P65, wherein the residue positions correspond to the positions 42, 43, 44, 45, 62, and 65 as set forth in SEQ ID NO: 1;
b. the modified IL-2 polypeptide comprises an N-terminal deletion comprising a deletion of the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 residues from the N-terminus, wherein the residue positions are in reference to the positions in SEQ ID NO: 1;
c. the conjugating moiety is polyethylene glycol (PEG) having a weight-average molecular weight of from about 20,000 Daltons to about 85,000 Daltons; and
d. the modified interleukin-2 (IL-2) polypeptide comprises at least 90% sequence identity to SEQ ID NO: 1.
16. The modified interleukin-2 (IL-2) polypeptide of claim 15 , wherein the modified IL-2 polypeptide comprises an N-terminal deletion comprising a deletion of the first 1, 2, 3, 4, or 5 residues from the N-terminus, wherein the residue positions are in reference to the positions in SEQ ID NO: 1.
17. The modified interleukin-2 (IL-2) polypeptide of claim 16 , wherein polyethylene glycol (PEG) has a weight-average molecular weight selected from about 20,000 Daltons, about 25,000 Daltons, about 30,000 Daltons, about 35,000 Daltons, about 40,000 Daltons, about 45,000 Daltons, or about 50,000 Daltons.
18. A pharmaceutical composition comprising a modified IL-2 polypeptide of claim 1 and a pharmaceutically acceptable excipient.
19. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition is formulated for systemic or parenteral delivery.
20. The modified interleukin-2 (IL-2) polypeptide of claim 1 , wherein the modified interleukin-2 (IL-2) polypeptide comprises at least 95% sequence identity to SEQ ID NO: 1.
21. The modified interleukin-2 (IL-2) polypeptide of claim 20 , wherein the position of the at least one unnatural amino acid is F42, wherein the residue position corresponds to position 42 as set forth in SEQ ID NO: 1.
22. The modified interleukin-2 (IL-2) polypeptide of claim 17 , wherein the modified interleukin-2 (IL-2) polypeptide comprises at least 95% sequence identity to SEQ ID NO: 1.
23. The modified interleukin-2 (IL-2) polypeptide of claim 22 , wherein the position of the at least one unnatural amino acid is K43, wherein the residue position corresponds to position 43 as set forth in SEQ ID NO: 1.
24. The modified interleukin-2 (IL-2) polypeptide of claim 23 , wherein the modified interleukin-2 (IL-2) polypeptide comprises at least 97% sequence identity to SEQ ID NO: 1.
25. The modified interleukin-2 (IL-2) polypeptide of claim 22 , wherein the position of the at least one unnatural amino acid is F44, wherein the residue position corresponds to position 44 as set forth in SEQ ID NO: 1.
26. The modified interleukin-2 (IL-2) polypeptide of claim 25 , wherein the modified interleukin-2 (IL-2) polypeptide comprises at least 97% sequence identity to SEQ ID NO: 1.
27. The modified interleukin-2 (IL-2) polypeptide of claim 22 , wherein the position of the at least one unnatural amino acid is E62, wherein the residue position corresponds to position 62 as set forth in SEQ ID NO: 1.
28. The modified interleukin-2 (IL-2) polypeptide of claim 27 , wherein the modified interleukin-2 (IL-2) polypeptide comprises at least 97% sequence identity to SEQ ID NO: 1.
29. The modified interleukin-2 (IL-2) polypeptide of claim 22 , wherein the position of the at least one unnatural amino acid is P65, wherein the residue position corresponds to position 65 as set forth in SEQ ID NO: 1.
30. The modified interleukin-2 (IL-2) polypeptide of claim 29 , wherein the modified interleukin-2 (IL-2) polypeptide comprises at least 97% sequence identity to SEQ ID NO: 1.